which drives the adaptive compartment of the immune system to initiate a systemic cytotoxic T lymphocyte (CTL) and T-helper 1 (Th-1) type T cell response. As a result, tumor-specific effector T ...

The global Phase III VANCE trial of the autologous EBV-targeted T-cell therapy was the largest trial of a solid tumor cell ...

The vaccine protected mice against pre-established tumors expressing ovalbumin, suggesting that this approach could be used for stimulating CTL activity against tumor-associated antigens in cancer ...

Strategies for modulating CTL-dependent immune responses during cellular immunotherapy ... We are particularly interested in engineering lymphocytes to target tumors with enhanced potency and ...